Reference

Determination of salvianolic acid in traditional Chinese medicine yangxinshengmaikeli by HPLC-photodiode array

All Rights Reserved. Determination of salvianolic acid in traditional Chinese medicine yangxinshengmaikeli by HPLC-photodiode array. Liu, Peng-yan; Wang, Hong-yu; Wang, Ying-feng; Li, Tian (College of Chemistry and Environmental Science, Hebei University, Baoding 071002, Peop. Rep. China). Hebei Daxue Xuebao, Ziran Kexueban, 26(3), 266-269 (Chinese) 2006 Hebei Daxue Bianjibu. 96574-01-5 is the cas registry number. This chemical is also mentioned in this article. CODEN: HDXKEB. ISSN: 1000-1565. DOCUMENT TYPE: Journal CA Section: 64 (Pharmaceutical Analysis) Section cross-reference(s): 80 An HPLC method for the detn. of salvianolic acid in yangxinshengmaikeli was established. The sepn. of salvianolic acid was carried out on Symmetry Shield RP18 column, with methanol-water-acetic acid (5:94.5:0.5) as mobile phase at flow rate of 1.0 mL/min and wavelength of 280 nm. Linear relationship was obtained in the range of 9.5-152 mg/L (R > 0.9999). The av. recovery was 98.9% and RSD (n = 5) was 0.97%. This study provided a simple, accurate, and feasible method for the detn. of salvianolic acid, and a usable integrated quality evaluation as well as a quality control for yangxinshengmaikeli. .

New formulations of traditional Chinese herb mixtures for preventing and treating hepatic fibrosis, and hepatitis B virus infections

All Rights Reserved. New formulations of traditional Chinese herb mixtures for preventing and treating hepatic fibrosis, and hepatitis B virus infections. Yuan, Ping; Mao, Rengang; Ren, Qingping; Lin, Donghao; Zhang, Hua; Qian, Xiuping; Hu, Gang (Shanghai Normal University; Shanghai Xinkang Pharmaceutical Factory, Peop. Rep. China). Faming Zhuanli Shenqing Gongkai Shuomingshu CN 1887316 A 3 Jan 2007, 19pp.In this study， 64-17-5 and 96574-01-5 are also used. (Chinese). (People's Republic of China). CODEN: CNXXEV. APPLICATION: CN 2010-27250 29 Jun 2005. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 The invention provides new formulations of traditional Chinese herb mixts. for preventing and treating hepatic fibrosis, and hepatitis B virus infections. The compn. comprises Coriolus versicolor, Panax notoginseng, Salvia miltiorrhiza, Sophora flavescens, and Paeonia lactiflora at a wt. ratio of 1:(0.2-5):(0.5-10):(0.5-10):(0.2-5). The prepn. method comprises (1) extg. mycelia or fruiting bodies of Coriolus versicolor with hot water, concg. the extractive soln., pptg. with ethanol, filtering, drying the ppt., and pulverizing to obtain an ext. contg. polysaccharide-peptide (PSP); (2) pulverizing the rest herbal materials, extg. with methanol, ethanol or water, concg. the extractive soln., dilg. with water, filtering, passing the filtrate through macroporous adsorptive resin column, rinsing with purified water, eluting with aq. soln. of low-mol. org. alc., concg. the eluate, and drying to obtain an ext. contg. effective fractions of the herbs; and (3) mixing the above two exts., and making into desired dosage form such as tablet, capsule, oral liq., granule, powder, injection, etc. The product contains PSP, salvianolic acid, ginsenoside Rg1, ginsenoside Rb1, matrine, oxymatrine, sophoridine and paeoniflorin, with total wt. 350% of the product. The inventive compn. can be used for treating hepatitis B and preventing and treating hepatic fibrosis and liver cirrhosis due to viral infection, drug, and alc. .